Anebulo Pharmaceuticals Inc (ANEB) - Total Liabilities
Based on the latest financial reports, Anebulo Pharmaceuticals Inc (ANEB) has total liabilities worth $1.49 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Anebulo Pharmaceuticals Inc growing its equity to track the company's year-over-year net asset growth rate.
Anebulo Pharmaceuticals Inc - Total Liabilities Trend (2020–2025)
This chart illustrates how Anebulo Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Anebulo Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Anebulo Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
N Citron Inc
KQ:101400
|
Korea | ₩8.16 Billion |
|
Visesh Infotecnics Limited
NSE:VISESHINFO
|
India | Rs606.65 Million |
|
Recharge Metals Ltd
AU:REC
|
Australia | AU$175.00K |
|
Sejoong Co. Ltd
KQ:039310
|
Korea | ₩15.13 Billion |
|
Adriatic Metals
LSE:ADT1
|
UK | GBX192.27 Million |
|
ChowChow Cloud International Holdings Limited
NYSE MKT:CHOW
|
USA | $33.73 Million |
|
Carlin Gold Corporation
V:CGD
|
Canada | CA$44.37K |
|
Natuzzi SpA
NYSE:NTZ
|
USA | $232.90 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Anebulo Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Anebulo Pharmaceuticals Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anebulo Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anebulo Pharmaceuticals Inc (2020–2025)
The table below shows the annual total liabilities of Anebulo Pharmaceuticals Inc from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $487.69K | +87.15% |
| 2024-06-30 | $260.58K | -75.62% |
| 2023-06-30 | $1.07 Million | +108.53% |
| 2022-06-30 | $512.53K | +112.11% |
| 2021-06-30 | $241.63K | +7.94% |
| 2020-06-30 | $223.87K | -- |
About Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical tria… Read more